vs
Side-by-side financial comparison of SMITH & WESSON BRANDS, INC. (SWBI) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $124.7M, roughly 1.0× SMITH & WESSON BRANDS, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -3.9%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -4.8%).
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
SWBI vs TVTX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $124.7M | $129.7M |
| Net Profit | $1.9M | — |
| Gross Margin | 24.3% | 98.0% |
| Operating Margin | 3.3% | -25.0% |
| Net Margin | 1.5% | — |
| Revenue YoY | -3.9% | 73.4% |
| Net Profit YoY | -53.6% | — |
| EPS (diluted) | $0.04 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $124.7M | $129.7M | ||
| Q3 25 | $85.1M | $164.9M | ||
| Q2 25 | $140.8M | $114.4M | ||
| Q1 25 | $115.9M | $81.7M | ||
| Q4 24 | $129.7M | $74.8M | ||
| Q3 24 | $88.3M | $62.9M | ||
| Q2 24 | $159.1M | $54.1M | ||
| Q1 24 | $137.5M | $41.4M |
| Q4 25 | $1.9M | — | ||
| Q3 25 | $-3.4M | $25.7M | ||
| Q2 25 | $8.6M | $-12.8M | ||
| Q1 25 | $2.1M | $-41.2M | ||
| Q4 24 | $4.5M | — | ||
| Q3 24 | $-1.9M | $-54.8M | ||
| Q2 24 | $27.9M | $-70.4M | ||
| Q1 24 | $7.9M | $-136.1M |
| Q4 25 | 24.3% | 98.0% | ||
| Q3 25 | 25.9% | 99.0% | ||
| Q2 25 | 28.8% | 98.7% | ||
| Q1 25 | 24.1% | 94.3% | ||
| Q4 24 | 26.6% | 96.6% | ||
| Q3 24 | 27.4% | 97.4% | ||
| Q2 24 | 35.5% | 96.2% | ||
| Q1 24 | 28.7% | 96.4% |
| Q4 25 | 3.3% | -25.0% | ||
| Q3 25 | -3.5% | 15.1% | ||
| Q2 25 | 9.3% | -11.1% | ||
| Q1 25 | 4.1% | -52.2% | ||
| Q4 24 | 5.8% | -81.2% | ||
| Q3 24 | -1.7% | -89.3% | ||
| Q2 24 | 17.4% | -125.1% | ||
| Q1 24 | 8.2% | -336.5% |
| Q4 25 | 1.5% | — | ||
| Q3 25 | -4.0% | 15.6% | ||
| Q2 25 | 6.1% | -11.1% | ||
| Q1 25 | 1.8% | -50.4% | ||
| Q4 24 | 3.5% | — | ||
| Q3 24 | -2.1% | -87.1% | ||
| Q2 24 | 17.5% | -130.1% | ||
| Q1 24 | 5.7% | -328.9% |
| Q4 25 | $0.04 | $0.04 | ||
| Q3 25 | $-0.08 | $0.28 | ||
| Q2 25 | $0.19 | $-0.14 | ||
| Q1 25 | $0.05 | $-0.47 | ||
| Q4 24 | $0.10 | $-0.71 | ||
| Q3 24 | $-0.04 | $-0.70 | ||
| Q2 24 | $0.60 | $-0.91 | ||
| Q1 24 | $0.17 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.4M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $363.2M | $114.8M |
| Total Assets | $548.6M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | $93.0M | ||
| Q3 25 | $18.0M | $110.9M | ||
| Q2 25 | $25.2M | $75.2M | ||
| Q1 25 | $26.7M | $61.9M | ||
| Q4 24 | $39.1M | $58.5M | ||
| Q3 24 | $35.5M | $36.4M | ||
| Q2 24 | $60.8M | $32.3M | ||
| Q1 24 | $47.4M | $43.3M |
| Q4 25 | $363.2M | $114.8M | ||
| Q3 25 | $364.4M | $73.6M | ||
| Q2 25 | $372.5M | $32.7M | ||
| Q1 25 | $366.9M | $32.8M | ||
| Q4 24 | $371.5M | $59.1M | ||
| Q3 24 | $380.0M | $-30.5M | ||
| Q2 24 | $399.9M | $15.1M | ||
| Q1 24 | $376.4M | $74.1M |
| Q4 25 | $548.6M | $605.2M | ||
| Q3 25 | $554.6M | $538.6M | ||
| Q2 25 | $559.6M | $555.3M | ||
| Q1 25 | $578.9M | $548.8M | ||
| Q4 24 | $587.4M | $594.1M | ||
| Q3 24 | $571.3M | $504.4M | ||
| Q2 24 | $577.4M | $551.1M | ||
| Q1 24 | $570.6M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.3M | $60.7M |
| Free Cash FlowOCF − Capex | $16.3M | — |
| FCF MarginFCF / Revenue | 13.1% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 14.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $21.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $60.7M | ||
| Q3 25 | $-8.1M | $14.3M | ||
| Q2 25 | $40.8M | $5.0M | ||
| Q1 25 | $-9.8M | $-42.2M | ||
| Q4 24 | $-7.4M | $-35.7M | ||
| Q3 24 | $-30.8M | $-42.5M | ||
| Q2 24 | $43.7M | $-40.2M | ||
| Q1 24 | $25.2M | $-119.0M |
| Q4 25 | $16.3M | — | ||
| Q3 25 | $-12.4M | $14.2M | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $-16.1M | — | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $38.2M | $-40.3M | ||
| Q1 24 | $7.0M | — |
| Q4 25 | 13.1% | — | ||
| Q3 25 | -14.6% | 8.6% | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | -13.9% | — | ||
| Q4 24 | -8.3% | — | ||
| Q3 24 | -40.2% | — | ||
| Q2 24 | 24.0% | -74.5% | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 8.8% | — | ||
| Q3 25 | 5.0% | 0.1% | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 5.3% | 0.0% | ||
| Q2 24 | 3.5% | 0.2% | ||
| Q1 24 | 13.2% | 0.0% |
| Q4 25 | 14.22× | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | 4.73× | — | ||
| Q1 25 | -4.68× | — | ||
| Q4 24 | -1.63× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 3.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SWBI
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
